Cardiosphere-derived cell (cdc) therapy for the treatment of viral infections
AssigneesCedars-Sinai Medical Center, Capricor, Inc.
InventorsEduardo Marbán, Linda Marbán
Life of this patent
Estimating the term…
Abstract
Several embodiments of the methods and compositions disclosed herein relate to methods of treating viral infections, such as those caused by coronaviruses. In some embodiments, CDCs are administered to a patient, to treat the viral infection. In some embodiments, CDC-derived exosomes are administered to a patient. In some embodiments combinations of CDCs and CDC-derived exosomes are used. In still additional embodiments, combination therapies, such as CDCs or CDC-derived exosomes in combination with another therapeutic, such as an anti-inflammotry or other immune modulator are used to treat viral infections. In some embodiments, the viral infection is COVID-19, which is caused by SARS-CoV-2.
Claims51
A method of treating a respiratory viral infection, comprising administering to a subject in need of treating a respiratory viral infection, or one or more symptoms or sequelae thereof, a therapeutically effective amount of cardiosphere-derived cells (CDCs) and/or CDC-derived exosomes, thereby treating the viral infection or one or more symptoms or sequelae thereof.
The method of any one of the preceding claims, further comprising administering to the subject at least one additional dose of the therapeutically effective amount of cardiosphere-derived cells (CDCs) and/or CDC-derived exosomes.
The method of claim any one of the preceding claims, further comprising administering to the subject at least one additional therapeutic, wherein the additional therapeutic is selected from an antiviral agent;
- an analgesic agent;
- anti-arthritic agent;
- anti-asthmatic agent;
- anticholinergic agent;
- antihistamine;
- anti-infective agent;
- anti-inflammatory agent;
- cardiovascular medicament;
- gastrointestinal medicament;
- immunosuppressive agent;
- leukotriene inhibitor;
- narcotic agonist or antagonist;
- peptide drug;
- phytonutrient;
- vasodilator;
- vitamins or mineral supplement, or a combination thereof.
The method of any one of the preceding claims, further comprising administering to the subject an anti-viral therapy.
A method of treating a respiratory viral infection, comprising administering to a subject in need of treating a respiratory viral infection, or one or more symptoms or sequelae thereof, a therapeutically effective amount of cardiosphere-derived cells (CDCs), thereby treating the respiratory viral infection or one or more symptoms or sequelae thereof,
- wherein the respiratory viral infection is COVID-19, wherein the therapeutically effective amount comprises from about 1×107 to about 1×109 CDCs, wherein administration of the therapeutically effective amount of CDCs reduces a hyperinflammatory response, or a sequelae thereof, associated with a SARS-CoV-2 infection.
A method of treating a respiratory viral infection, comprising:
- administering to a subject in need of treating a respiratory viral infection, or one or more symptoms or sequelae thereof, a population of cardiosphere-derived cells (CDCs) and/or CDC-derived exosomes, wherein the population comprises about 1×108 to about 2×108 CDCs and/or about 2×108 to about 2×1010 CDC-derived exosomes;
- and
- administering to the subject at least one additional therapeutic, wherein the additional therapeutic is selected from an antiviral agent, an antihistamine, anti-inflammatory agent, immunosuppressive agent, cyclooxygenase-2 inhibitor, TNF-α inhibitor, cytokine inhibitor or a combination thereof;
- wherein the administration of the CDCs and/or CDC-derived exosomes and the at least one additional therapeutic reduce one or more of respiratory distress, myocardial injury, and/or inflammatory cytokine level, thereby treating the respiratory viral infection or one or more symptoms or sequelae thereof.
The method of any one of the preceding claims, wherein the CDCs are allogeneic CDCs.
The method of any one of the preceding claims, wherein the exosomes are allogeneic CDC-derived exosomes.
The method of any one of the preceding claims, wherein the administering comprises parenteral administration of the population of CDCs and/or CDC-derived exosomes.
The method of any one of the preceding claims, wherein the population of CDCs and/or CDC-derived exosomes is administered intravenously.
The method of any one of the preceding claims, wherein the administering comprises infusing or injecting the population of CDCs and/or CDC-derived exosomes.
The method of any one of the preceding claims, wherein the administering comprises administering the CDCs.
The method of any one of the preceding claims, wherein the administering comprises administering the CDC-derived exosomes.
The method of any one of the preceding claims, wherein the subject has one or more comorbidities.
Use of a therapeutically effective amount of CDCs and/or CDC-derived exosomes, and optionally at least one additional therapeutic, wherein the additional therapeutic is selected from an antiviral agent, an antihistamine, anti-inflammatory agent, immunosuppressive agent, cyclooxygenase-2 inhibitor, TNF-α inhibitor, cytokine inhibitor or a combination thereof, for the treatment of a respiratory viral infection.
Use of a therapeutically effective amount of CDCs and/or CDC-derived exosomes, and optionally at least one additional therapeutic, wherein the additional therapeutic is selected from an antiviral agent, an antihistamine, anti-inflammatory agent, immunosuppressive agent, cyclooxygenase-2 inhibitor, TNF-α inhibitor, cytokine inhibitor or a combination thereof, in the manufacture of a medicament for the treatment of a respiratory viral infection.
Dependencies are inferred from the claim text.